Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: Pooled 96 week results from the phase III DUET trials

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 11, 2010, Pages 2450-2454

  Clotet, Bonaventura ^a,b   Clumeck, Nathan ^c   Katlama, Christine ^d   Nijs, Steven ^e   Witek, James ^f  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b IrsiCaixa Foundation   (Spain)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e TIBOTEC BVBA   (Belgium)

^f Tibotec Inc   (United States)

Author keywords

HBV; HCV; Non nucleoside reverse transcriptase inhibitors; TMC125; Treatment experienced

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; PLACEBO; VIRUS RNA;

ANEMIA; ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIXED INFECTION; MODEL FOR END STAGE DISEASE SCORE; NAUSEA; SCORING SYSTEM; SIDE EFFECT; THRUSH; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; PLACEBOS; PYRIDAZINES;

EID: 77957860626     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq332     Document Type: Article

References (11)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6-9.
2. Soriano V, Vispo E, Labarga P et al. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85: 303-15.
3. Brau N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
4. den Brinker M, Wit FWNM, Wertheim-van Dillen PME et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895-902.
5. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 59: 342-6.
6. Katlama C, Haubrich R, Lalezari J et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
7. Trottier B, Mills A, Cahn P et al. Durable efficacy and safety of etravirine (ETR; TMC125) in treatment-experienced, HIV-1-infected patients: pooled Week 96 results from the Phase III DUET-1 and DUET-2 trials. In: Abstracts of the Eighteenth Annual Canadian Conference on HIV/AIDS Research, Vancouver, Canada, 2009. Abstract P148. Can J Infect Dis Med Microbiol 2009; 20 Suppl B: 53B.
8. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
9. Ammassari A, Cozzi-Iepri A, Trotta MP et al. The relative role of HCV coinfection, adherence to antiretrovirals and plasma drug levels on the incidence of ALT elevation during HAART. In: Abstracts of the Third IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 2005. Abstract TuPe1.1C29.
10. Torti C, Lapadula G, Casari S et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis 2005; 5: 58-68.
11. Tibotec Inc. PREZISTA® (darunavir) Prescribing Information 2006; Revised April 2010. www.prezista.com (7 July 2010, date last accessed).